Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Skerget M et al. Radiol Oncol. 2016 May 12;50(4):402-408. eCollection 2016.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II trial.
Mey UJ et al. Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14481. [Epub ahead of print].
Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.
Kwon J et al. Cancer Med. 2016 Dec 1. doi: 10.1002/cam4.970. [Epub ahead of print].